Yamauchi R, Ito T, Yoshio S, Yamamoto T, et al. Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. J Gastroenterol 2023 Mar 30. doi: 10.1007/s00535-023-01985.
PMID: 36991155